Join us on Wednesday, August 12 for the live webinar
5:00 PM – 6:30 PM ET
1.5 AMA PRA Category 1 Credits^TM

Not an official event of ASCO20 Virtual. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Grail Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, and Taiho Oncology Inc.

First-Line Systemic Therapy for Patients with Unresectable Hepatocellular Carcinoma (HCC) — Dr Venook

• Clinical and biologic factors affecting the selection of first-line treatment for advanced HCC (eg, age, symptomatology, liver function)
• Available Phase III data with and FDA approval of lenvatinib as first-line therapy for unresectable HCC
• Design, entry criteria and key efficacy and safety findings of the Phase III IMbrave150 trial comparing atezolizumab/bevacizumab to sorafenib as first-line therapy for unresectable HCC
• FDA approval and optimal integration of atezolizumab/bevacizumab as first-line therapy for unresectable HCC
• Results from the Phase Ib KEYNOTE-524/Study 116 trial evaluating pembrolizumab in combination with lenvatinib as first-line treatment for advanced unresectable HCC; FDA breakthrough therapy designation and future development plans
• Active Phase III trials attempting to improve outcomes for patients with newly diagnosed advanced HCC (eg, LEAP-002, COSMIC-312)

Selection and Sequencing of Therapies for Patients with Progressive Metastatic HCC — Dr Philip

• Key efficacy and safety outcomes supporting the use of regorafenib for patients with progressive HCC
• Design of and key efficacy outcomes from the Phase III CELESTIAL trial comparing cabozantinib to placebo for patients whose disease has progressed on at least 1 prior systemic therapy for advanced HCC; FDA approval and nonresearch role of cabozantinib in progressive HCC
• Published results from the Phase III REACH-2 trial evaluating ramucirumab versus placebo for patients with AFP-elevated (≥400) HCC that has progressed on prior sorafenib; FDA approval and optimal integration into current treatment algorithms
• Published efficacy and safety data with the use of single-agent immune checkpoint inhibitor therapy in patients with progressive HCC
• Efficacy and safety findings from the CheckMate 040 trial leading to the FDA approval of nivolumab/ipilimumab in patients with relapsed HCC; current clinical role
• Early safety and efficacy with, potential clinical role and ongoing evaluation of durvalumab/tremelimumab in HCC

Contemporary Treatment Approaches for Patients with Localized Pancreatic Cancer — Dr Bekaii-Saab

• Findings from the Circulating Cell-free Genome Atlas study evaluating the potential role of a circulating free DNA assay to detect gastrointestinal cancers; accuracy and clinical relevance of results
• Use of contemporary chemotherapy regimens (mFOLFIRINOX, nab paclitaxel/gemcitabine) with or without radiation therapy as neoadjuvant treatment for resectable or borderline-resectable pancreatic adenocarcinoma (PAD)
• Selection of adjuvant systemic therapy for patients with resected PAD
• Key efficacy results from the Phase III APACT trial evaluating adjuvant nab paclitaxel/gemcitabine versus gemcitabine alone; clinical applicability of the results and role, if any, of nab paclitaxel/gemcitabine in the adjuvant setting

Optimal Management of Metastatic Pancreatic Cancer — Dr O’Reilly

• Optimal selection of first- and later-line treatment for metastatic PAD; effects of age, PS, comorbidities and prior neoadjuvant or adjuvant therapy
• Published research experience with, patient selection for and practical integration of nanoliposomal irinotecan (nal-IRI) for relapsed metastatic PAD
• Available data with and ongoing evaluation of nal-IRI in earlier disease settings
• Design, entry criteria and key efficacy and safety findings from the Phase III POLO trial evaluating olaparib as maintenance therapy for patients with metastatic PAD and a germline BRCA mutation after first-line chemotherapy
• FDA approval of maintenance olaparib, implications for genetic testing and current clinical care of patients with metastatic BRCA-mutated PAD
• Ongoing investigation of other novel approaches in metastatic PAD

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.

Learning Objectives

• Acknowledge available Phase III data with and the FDA approval of lenvatinib as first-line treatment for unresectable hepatocellular carcinoma (HCC), and discern how this agent can be optimally integrated into the clinical care of patients with this disease.
• Evaluate Phase III data leading to the recent FDA approval of atezolizumab in combination with bevacizumab as first-line therapy for patients with newly diagnosed unresectable or metastatic HCC, and consider the current role of this novel regimen.
• Recall available clinical trial data with approved and investigational systemic interventions, and where appropriate, apply this information to the current clinical care of patients with locally advanced or metastatic HCC.
• Maintain an understanding of the side effects and toxicities associated with targeted agents and immunotherapeutic approaches used in the management of advanced HCC to facilitate early and effective responses to various adverse events.
• Consider age, performance status, prior therapeutic exposure and other clinical and logistical factors in the selection and sequencing of systemic therapy for patients with unresectable or metastatic HCC or locally advanced or metastatic pancreatic adenocarcinoma (PAD).
• Appreciate the efficacy and tolerability profile of nanoliposomal irinotecan (nal-IRI) for treatment-refractory metastatic PAD, and optimally incorporate this agent into patient-care algorithms.
• Appraise available Phase III data leading to the FDA approval of olaparib maintenance after first-line platinum-based chemotherapy for patients with newly diagnosed PAD and a germline BRCA mutation, and consider the diagnostic and therapeutic implications of these findings on clinical practice.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Bekaii-Saab — Advisory Committee: Immuneering Corporation, Imugene, Sun BioPharma Inc; Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Natera Inc, Seattle Genetics, Sobi, Treos Bio; Contracted Research: AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merus BV, Mirati Therapeutics, Novartis, Seattle Genetics; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Lilly, Merck, Pancreatic Cancer Action Network. Dr O’Reilly — Consulting Agreements: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Halozyme Inc. Dr Philip — Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Ipsen Biopharmaceuticals Inc, Merck, Merus BV, Pfizer Inc, QED Therapeutics, Rafael Pharmaceuticals Inc; Consulting Agreements: Blueprint Medicines, Erytech, SynCore Biotechnology Co Ltd, TriSalus Life Sciences; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, BeiGene, Bristol-Myers Squibb Company, Celgene Corporation, Five Prime Therapeutics Inc, Forty Seven Inc, Incyte Corporation, Karyopharm Therapeutics, Merck, Merus BV, Novartis, Novocure, QED Therapeutics, Rafael Pharmaceuticals Inc, SynCore Biotechnology Co Ltd, Taiho Oncology Inc, Tyme Inc; Data and Safety Monitoring Board/Committee: ASLAN Pharmaceuticals, Blueprint Medicines, Erytech; Speakers Bureau: Advanced Accelerator Applications, Celgene Corporation, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Novartis. Dr Venook — Advisory Committee: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Roche Laboratories Inc; Contracted Research: Amgen Inc, Genentech, a member of the Roche Group, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
— Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Grail Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, and Taiho Oncology Inc.